NamibiaTuberculosis profile
Population  2015 2.5 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.78 (0.51–1.1) 32 (21–45)
Mortality (HIV+TB only) 0.88 (0.062–2.8) 36 (2.5–112)
Incidence  (includes HIV+TB) 12 (9.3–15) 489 (376–616)
Incidence (HIV+TB only) 4.9 (3.8–6.2) 199 (153–252)
Incidence (MDR/RR-TB)** 1.1 (0.84–1.3) 45 (34–53)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.57 (0.27–0.87) 4.4 (2.8–6) 5 (3–6.9)
Males 0.63 (0.39–0.86) 6.4 (4.8–8) 7.1 (5.2–8.9)
Total 1.2 (0.82–1.6) 11 (9.2–12) 12 (9.3–15)
TB case notifications, 2015  
Total cases notified 9 944
Total new and relapse 9 614
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 98%
          - % pulmonary 83%
          - % bacteriologically confirmed among pulmonary 76%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 80% (64–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.14 (0.05–0.3)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 3 796 40%
          - on antiretroviral therapy 3 480 92%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  540
(470–610)
Estimated % of TB cases with MDR/RR-TB 5% (4.1–5.9) 12% (9.3–14)  
% notified tested for rifampicin resistance     320
MDR/RR-TB cases tested for resistance to second-line drugs    
Laboratory-confirmed cases MDR/RR-TB: 320, XDR-TB: 3
Patients started on treatment **** MDR/RR-TB: 308, XDR-TB: 2
Treatment success rate and cohort size Success Cohort
New cases registered in 2014 87% 7 981
Previously treated cases registered in 2014 78% 2 068
HIV-positive TB cases, all types, registered in 2014 80% 3 112
MDR/RR-TB cases started on second-line treatment in 2013 64% 184
XDR-TB cases started on second-line treatment in 2013 0% 6
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 38
Funding source: 51% domestic, 26% international, 23% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-11 Data: www.who.int/tb/data